Completed PHASE2/PHASE3 INTERVENTIONAL 5-arm NCT00377598

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo

Sponsor: Takeda

Conditions Neuralgia, Postherpetic

Interventions Placebo TAK-583

Updated 6 times since 2017 Last updated: Jan 31, 2012 Started: Oct 31, 2006 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Neuralgia, Postherpetic and is currently completed. Takeda leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amanzimtori, South Africa , Arnhem, Netherlands , Berlin, Germany , Bloemfontein, South Africa , Box Hill, Australia , Breda, Netherlands , Breyten, South Africa , Carlton, Australia , Chichester, United Kingdom , Darlington, United Kingdom and 38 more locations